ORLANDO, FLORIDA, December 11, 2001 -- According to studies presented at the 43rd annual meeting of the American Society of Hematology (ASH), Bexxar (tositumomab and iodine I 131 tositumomab), an investigational radioimmunotherapy being studied for the treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL), provides durable, long-term responses when used either alone or following chemotherapy. Multiple presentations suggest that Bexxar, currently under review at the U.S. Food and Drug Administration (FDA), may offer an important new treatment option for relapsed or refractory NHL patients, and in particular for patients whose prognosis is usually very poor.
Reports of Durable, Objective Responses
Analysis of data on 582 patients with relapsed, refractory low-grade or transformed low-grade NHL who received Bexxar in clinical trials from 1990-2000, by John Leonard, M.D., clinical director, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York, and his colleagues, showed that Bexxar produced an overall response (defined as a reduction of at least 50 percent in overall tumor burden) in 57 percent of patients, half of whom remained in remission for 14.3 months or more [ASH Abstract #2527]. Furthermore, 28 percent of all patients showed a complete response (total elimination of disease confirmed by clinical or radiological evaluation) to Bexxar therapy, half of whom remained in remission for 4.8 years or longer. The average follow-up was 1.3 years with a maximum of 8.5 years.
"These results provide further evidence that Bexxar produces durable responses in patients with either low-grade or transformed low-grade NHL," said Dr. Leonard.
Novel First-Line Triple Modality Therapy
To evaluate a new approach to previously untreated NHL, investigators treated 35 patients in a clinical trial of "triple modality" therapy, the combination of chemotherapy (fludarabine), radiation (IPage: 1 2 3 4 5 Related biology news :1
Contact: Julie McQuain
JMPR Associates, Inc.
. Protective gene may enhance vaccine responses2
. Small gene changes in some leukemia patients may explain varying responses to chemotherapy3
. Planning effective bioterror responses4
. UB researchers show first evidence of pharmacogenomic differences in patients responses to MS drug5
. UBC researcher discovers control room that regulates immune responses6
. U of MN researchers find genetic variations may predict treatment responses for myeloma7
. New study sheds light on the responses to diuretics8
. Scientists discover how to grow cells that suppress immune responses9
. T cell responses in aplastic anemia10
. Symposium to highlight regulation of plant immune responses11
. Aspirin targets key cell that triggers organ rejection and other immune responses, report University of Pittsburgh researchers in journal article